NCT06654050 2026-03-17
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
University of Florida
University of Alabama at Birmingham